December 2001
Worldwide Biotech;Dec2001, Vol. 13 Issue 12, p1
Trade Publication
Focuses on Nordic Bioscience A/S biotechnology firm, the merger of Osteometer Biotech A/S and Osteopro A/S. Location of Nordic Bioscience; Significance of the merger; Information on the company's research within osteoporosis.


Related Articles

  • Radius Health Raises $91M for Osteoporosis Phase III Trial. Wall, Tom // BioWorld Today;5/25/2011, Vol. 22 Issue 101, p1 

    The article reports on the 91 million U.S. dollars raised by Cambridge, Massachusetts-based Radius Health Inc. for a Phase III trial of lead candidate BA058 for the treatment of osteoporosis. According to the company, it began the process of becoming a public company via a merger with a shell...

  • WEEK IN REVIEW.  // BioWorld Insight;10/10/2011, Vol. 19 Issue 41, p5 

    The article offers news briefs related to biotechnology companies in the U.S. Creabilis SA raised 20 million dollars worth of Series B financing. Agios Pharmaceuticals Inc. obtained 20 million dollars from its partner Celgene Corp. for the extension of its cancer metabolism deal. Nordic...

  • Oral Calcitonin Phase III in OA Patients Will Continue. Hollingsworth, Catherine // BioWorld Today;7/26/2010, Vol. 21 Issue 142, p1 

    The article reports on the decision of Novartis Pharma AG to continue its Phase III study of oral calcitonin in patients with osteoarthritis (OA) despite the efficacy issues raised by an independent data safety monitoring committee. According to updates filed with the U.S. government-run website...

  • The biotech blues? Don't sing that tune around here. Hogg, Michael // Crain's Chicago Business;4/8/2002, Vol. 25 Issue 14, p11 

    Comments on issues concerning the biotechnology community in Illinois. List of things needed to capitalize the projected growth of the biotechnology industry; Reference to the merger of Monsanto and Pharmacia & Upjohn; Establishment of the Illinois Biotechnology Industry Organization.

  • Research collaborations.  // Nature Biotechnology;Apr2000, Vol. 18 Issue 4, p367 

    Presents research collaborations in the biotechnology sector as of April 2000. Companies involved in the collaborations; Details of the collaboration.

  • Battered Biotech Remains Driver for Innovation As M&As Surge. Jarvis, Lisa // Chemical Market Reporter;3/3/2003, Vol. 263 Issue 9, p6 

    Reports on merger and acquisition trends in the biotechnology industry. Challenges faced by the industry; Factors affecting the performance of the industry; Increase in worldwide biotechnology merger activities in 2001.

  • Biotech companies adopt pharmaco's merger mania.  // Medical Marketing & Media;Jan2002, Vol. 37 Issue 1, p18 

    Reports the growing acquisition trends in the biotechnology industry. Merger between Millennium Pharmaceuticals and Cor Therapeutics; Value of the acquisition Aviron by Medimmune; Terms of the deal between Cephalon and Group Lafon.

  • Consolidation revisited. Williams, Alan // Journal of Commercial Biotechnology;Autumn2001, Vol. 8 Issue 2, p130 

    In 1998, the author produced two papers that argued that consolidation was a necessary activity for biotechnology companies to pay greater attention to. Three years later a further consideration of the subject seems worthwhile. Examples of successful consolidators are reviewed.

  • UK industry consolidation is slow despite big merger. Mitchell, Peter // Nature Biotechnology;Mar2003, Vol. 21 Issue 3, p215 

    Reports on the state of merger and consolidation of the biotechnology industry in Great Britain. Acquisition of Oxford GlycoSciences by Cambridge Antibody Technology; Benefits of the merger for both companies; Impact of the merger on other biotechnology firms.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics